Skip to main content
. Author manuscript; available in PMC: 2015 Jan 8.
Published in final edited form as: J Cell Biochem. 2008 Dec 1;105(5):1183–1193. doi: 10.1002/jcb.21899

Figure 3. HIP/RPL29 partially inhibits VEGF receptor-2 activation.

Figure 3

Western blotting for total VEGF receptor-2 (VEGFR2) and phospho-VEGFR2 was performed as described in Materials and Methods. Panels A and C show representative blots for duplicate treatment groups for phosphorylation at Y-996 and Y-951, respectively. Panels B and D show the corresponding densitometirc analyses of the ratio of VEGFR2 phosphorylation at Y-996 and Y-951, respectively, relative to total VEGFR2. *, p<0.05 relative to control (no VEGF or HIP/RPL29).